Help us improve Portfolio Grader.

Help us improve Portfolio Grader.

Blue Chip Growth

Stock Report: "MiMedx Group, Inc." (MDXG) Report Updated: Mar 23, 2015 | Print This Page

Get more stock ratings by Louis Navellier

"MiMedx Group, Inc." (MDXG)

Rating: Buy Volatility: Aggressive
Total Grade: B Industry: Biotechnology
Competitors: REGN, ESPR, AGIO, GILD

Stock Analysis

Rating: Monthly View

March April May June July August September October November December January February

Rating: Weekly View

This Week: B down no change
Last Week: B same no change
Two Weeks Ago: B up no change
service keys

"MiMedx Group, Inc."© quotemedia

Company Profile

MiMedx Group, Inc., together with its subsidiaries, operates as an integrated developer, manufacturer, and marketer of patent protected regenerative biomaterial products and allografts processed from human amniotic membranes. Its biomaterial platform technologies include HydroFix and CollaFix device technologies; and AmnioFix and EpiFix tissue technologies. Its tissue technologies, processed from the human amniotic membrane, utilize its proprietary Purion process to produce minimally manipulated implants. The company supplies amniotic tissues to distributors and original equipment manufacturers for application in the surgical, ophthalmic, orthopedics, spine, wound care, and dental sectors of healthcare. MiMedx Group sells its products directly, as well as through a network of third party sales agents and stocking distributors in the United States and internationally. The company is headquartered in Kennesaw, Georgia.

Recent News: "MiMedx Group, Inc."